GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuCell Corp (NAS:ICCC) » Definitions » Beneish M-Score

ImmuCell (ImmuCell) Beneish M-Score : -2.12 (As of Apr. 27, 2024)


View and export this data going back to 1995. Start your Free Trial

What is ImmuCell Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.12 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for ImmuCell's Beneish M-Score or its related term are showing as below:

ICCC' s Beneish M-Score Range Over the Past 10 Years
Min: -3.56   Med: -2.45   Max: -1.99
Current: -2.12

During the past 13 years, the highest Beneish M-Score of ImmuCell was -1.99. The lowest was -3.56. And the median was -2.45.


ImmuCell Beneish M-Score Historical Data

The historical data trend for ImmuCell's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuCell Beneish M-Score Chart

ImmuCell Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.56 -2.77 -2.23 -2.91 -2.12

ImmuCell Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.91 -2.38 -1.99 -1.92 -2.12

Competitive Comparison of ImmuCell's Beneish M-Score

For the Biotechnology subindustry, ImmuCell's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ImmuCell's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuCell's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where ImmuCell's Beneish M-Score falls into.



ImmuCell Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of ImmuCell for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.3128+0.528 * 1.8597+0.404 * 0.8504+0.892 * 0.941+0.115 * 0.9635
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0173+4.679 * -0.033282-0.327 * 1.3305
=-2.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $2.23 Mil.
Revenue was 5.096 + 5.397 + 3.533 + 3.447 = $17.47 Mil.
Gross Profit was 1.258 + 1.267 + 1.044 + 0.301 = $3.87 Mil.
Total Current Assets was $11.47 Mil.
Total Assets was $43.81 Mil.
Property, Plant and Equipment(Net PPE) was $32.15 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.72 Mil.
Selling, General, & Admin. Expense(SGA) was $5.22 Mil.
Total Current Liabilities was $4.20 Mil.
Long-Term Debt & Capital Lease Obligation was $14.62 Mil.
Net Income was -1.14 + -0.94 + -1.38 + -2.315 = $-5.78 Mil.
Non Operating Income was 0 + 0.365 + 0 + -0.008 = $0.36 Mil.
Cash Flow from Operations was -0.723 + -0.508 + -0.681 + -2.762 = $-4.67 Mil.
Total Receivables was $1.80 Mil.
Revenue was 3.911 + 4.796 + 3.861 + 6 = $18.57 Mil.
Gross Profit was 0.992 + 1.846 + 1.707 + 3.103 = $7.65 Mil.
Total Current Assets was $14.00 Mil.
Total Assets was $44.86 Mil.
Property, Plant and Equipment(Net PPE) was $30.64 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.49 Mil.
Selling, General, & Admin. Expense(SGA) was $5.46 Mil.
Total Current Liabilities was $3.07 Mil.
Long-Term Debt & Capital Lease Obligation was $11.41 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2.225 / 17.473) / (1.801 / 18.568)
=0.127339 / 0.096995
=1.3128

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(7.648 / 18.568) / (3.87 / 17.473)
=0.411891 / 0.221485
=1.8597

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (11.47 + 32.147) / 43.808) / (1 - (13.995 + 30.636) / 44.861)
=0.00436 / 0.005127
=0.8504

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=17.473 / 18.568
=0.941

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.487 / (2.487 + 30.636)) / (2.717 / (2.717 + 32.147))
=0.075084 / 0.077931
=0.9635

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(5.222 / 17.473) / (5.455 / 18.568)
=0.298861 / 0.293785
=1.0173

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((14.618 + 4.197) / 43.808) / ((11.409 + 3.072) / 44.861)
=0.429488 / 0.322797
=1.3305

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-5.775 - 0.357 - -4.674) / 43.808
=-0.033282

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

ImmuCell has a M-score of -2.12 suggests that the company is unlikely to be a manipulator.


ImmuCell Beneish M-Score Related Terms

Thank you for viewing the detailed overview of ImmuCell's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmuCell (ImmuCell) Business Description

Traded in Other Exchanges
Address
56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. It has two segments Scours and Mastitis. The company generates the majority of its revenue from the United States.
Executives
Bryan K. Gathagan director 56 EVERGREEN DRIVE, PORTLAND ME 04103
David Cunningham director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Gloria F Basse director 56 EVERGREEN DRIVE, PORTLAND ME 04103
David Scott Tomsche director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Steven T. Rosgen director C/O IMMUCELL CORPORATION, 56 EVERGREEN DR., PORTLAND ME 04103
Norman H Pessin other: See Explanation of Responses C/O LEVY, HARKINS & CO., INC., 366 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Brian L. Pessin other: See Explanation of Responses 310 EAST 75TH STREET, APT. 2A, NEW YORK NY 10021
Joseph H Crabb director, officer: Vice President and CSO IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Elizabeth Luttrell Williams officer: Vice Pres. of Mfg Operations C/O IMMUCELL CORPORATION, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Jonathan E Rothschild director, 10 percent owner C/O IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Linda Rhodes director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Paul R Wainman director 56 EVERGREEN DRIVE, PORTLAND ME 04103
Michael F Brigham director, officer: President and CEO IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Bobbi Jo Kunde other: Director of Sales and Marketin 56 EVERGREEN DRIVE, PORTLAND ME 04103
Robert C Bruce director 56 EVERGREEN DRIVE, PORTLAND ME 04103